Y Intercept (Hong Kong) LTD Sage Therapeutics, Inc. Transaction History

Y Intercept (Hong Kong) LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$10.58 - $17.9 $233,754 - $395,482	22,094 New	22,094 $239,000
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $356,663 - $522,403	8,774 New	8,774 $412,000
Q4 2022 Feb 14, 2023	BUY	$32.2 - $43.61 $259,210 - $351,060	8,050 New	8,050 $307,000
Q2 2022 Aug 08, 2022	SELL	$27.52 - $37.99 $254,972 - $351,977	-9,265 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$30.71 - $45.71 $284,528 - $423,503	9,265 New	9,265 $307,000
Q1 2021 May 12, 2021	SELL	$70.65 - $96.76 $625,605 - $856,809	-8,855 Closed	0 $0
Q4 2020 Feb 05, 2021	BUY	$58.41 - $89.06 $517,220 - $788,626	8,855 New	8,855 $785,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.